Korea's homegrown drug set to post record sales
Annual sales of a diabetes drug manufactured by LG Life Sciences Ltd., the pharmaceuticals unit of South Korea’s LG Group, are likely to exceed 50 billion won ($44.9 million) this year, the drug firm said Wednesday. It would mark the first time for the annual sales of a single homegrown drug to breach the 50 billion-won mark. The combined sales of Zemiglo , which was approved as the nation’s 19th new drug in 2012, and its composite drug Zemimet came to [...]